Aticaprant is being explored primarily for its potential in treating mood disorders, particularly depression. It functions as a kappa opioid receptor antagonist, which may help regulate mood and alleviate symptoms of depression by modulating the brain's stress response systems. Research suggests it could be particularly effective for individuals who have not responded well to traditional antidepressants. Clinical trials are ongoing to assess its efficacy and safety, with a focus on its ability to improve emotional resilience and reduce depressive symptoms. If successful, it could offer a novel therapeutic option for patients with treatment-resistant depression.